Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Refractory Anemia With Excess BlastsAdult Acute Myelomonocytic Leukemia (M4)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01607645
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT01518556
- Locations
- 🇰🇷
Division of Hematology-Oncology, Konkuk University Medical Center, Seoul, Korea, Republic of
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2016-07-13
- Target Recruit Count
- 50
- Registration Number
- NCT01484171
- Locations
- 🇨🇳
The Affiliated Hospital of the Chinese Academy of Military Medical Science, Beijing, Beijing, China
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
- Conditions
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 55
- Registration Number
- NCT01435343
- Locations
- 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
- Conditions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT01296178
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 282
- Registration Number
- NCT01289457
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine
- Conditions
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 277
- Registration Number
- NCT01180322
- Locations
- 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinikum Schleswig-Holstein, Kiel, Germany
🇦🇹Krankenhaus der Barmherzigen Schwestern, Linz, Austria
Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 11
- Registration Number
- NCT01154439
- Locations
- 🇮🇹
Università La Sapienza, Roma, Italy
🇮🇹Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia, Napoli, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Untreated Adult Acute Myeloid Leukemiade Novo Myelodysplastic SyndromesMyelodysplastic Syndrome With Isolated Del(5q)
- Interventions
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT01141725
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARASecondary Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11de Novo Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAlkylating Agent-Related Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT01132586
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.